Detailed translationalresearch correlative efforts will need to be systematically coupled with clinical trialsevaluating efficacy of PI3K inhibitors in breast cancers, as this will enhance ourunderstanding of responders and non-responders by providing the complete genomiclandscape associated with PIK3CA mutations and treatment response. Here, PIK3CB is linked to breast cancer.